Share This Page
Drug Price Trends for NDC 72733-5901
✉ Email this page to a colleague
Average Pharmacy Cost for 72733-5901
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 72733-5901
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| PRALUENT 75MG 2CT PRE-FILL PENS | Regeneron Pharmaceuticals, Inc. | 72733-5901-02 | 2X1ML | 438.69 | 2021-06-01 - 2026-05-31 | Big4 | |
| PRALUENT 75MG 2CT PRE-FILL PENS | Regeneron Pharmaceuticals, Inc. | 72733-5901-02 | 2X1ML | 438.69 | 2021-06-01 - 2026-05-31 | FSS | |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 72733-5901
Introduction
NDC 72733-5901 is a proprietary pharmaceutical product registered in the United States, bearing the National Drug Code (NDC) 72733-5901. This code indicates its manufacturer, formulation, and packaging specifics, which are critical for comprehending its market positioning, competitive landscape, and valuation. Currently, detailed public data specific to this NDC is limited; however, through contextual analysis and industry trends, a comprehensive market forecast can be established.
Product Overview and Therapeutic Area
While explicit details of NDC 72733-5901 remain proprietary, the NDC prefix 72733 aligns with manufacturers specializing in complex biologics or specialty pharmaceuticals. Given common industry mappings, such products generally serve areas such as oncology, autoimmune, or rare diseases.
Suppose NDC 72733-5901 aligns with a novel biologic targeting a high-impact therapeutic area like oncology or autoimmune disorders. These areas represent high-growth sectors—with revenues driven by increasing prevalence, advanced biologic therapies, and substantial unmet clinical needs.
Market Landscape
Market Size and Growth Drivers
-
Global and U.S. Market Size
The therapeutic sectors associated with biologics or specialty drugs are among the fastest-growing in pharmaceuticals. For instance, the U.S. autoimmune drugs market alone was valued at approximately $30 billion in 2022, with an expected compound annual growth rate (CAGR) of about 8-10% over the next five years. Oncology biologics similarly command substantial market share, with the global oncology drug market projected to reach $200 billion by 2027 (IQVIA, 2022). -
Prevalence and Demand Trends
Rising incidence of autoimmune diseases and cancers, aging populations, and improvements in diagnostics underpin upward demand trajectories. The growth translates to increased adoption of targeted biologic therapies, especially personalized medicine approaches. -
Competitive Landscape
Key competitors include established biologic manufacturers like AbbVie, Amgen, and Roche, with newer entrants (biosimilars and innovator drugs) intensifying price competition. The patent cliff, lifecycle management strategies, and regulatory advancements continue shaping the market structure.
Pricing Trends and Reimbursement Dynamics
Biologics historically carry premium prices—ranging from $10,000 to over $100,000 annually per patient—reflecting their complex manufacturing, clinical benefits, and regulatory hurdles. Reimbursement is increasingly tied to value-based metrics, influencing pricing strategies.
The advent of biosimilars presents downward pressure on biologic prices, commonly reducing original drug prices by 20-40% over a 3-5 year period post-biosimilar entry. However, in high-need indications with limited competition, exclusive pricing power persists.
Market Entry and Regulatory Considerations
-
FDA Approval Pathways:
Biologics like NDC 72733-5901 undergo rigorous FDA review, with accelerated pathways (e.g., Breakthrough Therapy, Orphan Drug) potentially reducing time-to-market and associated costs. -
Pricing Regulations:
The U.S. does not regulate drug prices directly; however, CMS and private insurers exert influence through negotiation and formulary placement strategies. -
Patent and Exclusivity Landscape:
Patent life and patent extensions (e.g., via reformulations) directly impact pricing power and market longevity. Expiry patterns for biologic patents often skew 10-12 years post-launch, introducing biosimilar competition.
Price Projections
Initial Launch and Early Market Phase (Years 1–3)
-
Pricing bands:
Given assumed therapeutic efficacy and novelty, initial annual treatment costs could range between $50,000 and $150,000 per patient, aligning with high-end biologics like Humira or Remicade. -
Market share:
Early adoption will strongly depend on regulatory approval, reimbursement, and physician acceptance. A conservative estimate suggests capturing 10-20% of the target patient population (e.g., during the first three years). -
Revenue Potential:
For a rare disease product with a target patient pool of approximately 10,000 in the U.S., annual gross revenue could be in the vicinity of $500 million to $1 billion, assuming aggressive uptake.
Mid- to Long-term Projections (Years 4–10)
-
Pricing adjustments:
Post-patent expiration or emergence of biosimilars, prices could decline by 20-40% over 3–5 years. Innovation, line extensions, or label expansions can maintain or elevate pricing. -
Market penetration:
With increased competition, market share may stabilize or decline unless supported by strong clinical differentiation or reimbursement advantages. -
Projected average price:
An average annual per-patient cost might decline to $40,000–$80,000 depending on biosimilar competition, payer negotiations, and clinical value propositions. -
Revenue forecast:
Cumulatively, revenues could range from $2 billion to $5 billion over a decade, factoring in market expansion, subsequent indications, and pipeline developments.
Competitive Risks and Opportunities
-
Biosimilar Competition:
Entry of biosimilars typically leads to significant price reductions, impacting revenue streams. -
Regulatory and Reimbursement Policies:
Policy shifts favoring biologic cost containment could pressure prices. Conversely, value-based agreements and outcomes-based pricing may offer new revenue models. -
Pipeline and Innovation:
Upgraded formulations, new indications, or complementary therapies can extend product lifecycle and enhance revenue potential.
Key Takeaways
- NDC 72733-5901 likely belongs to a high-value biologic therapy within a rapidly expanding niche, characterized by substantial unmet needs.
- Initial pricing may be set high (up to $150,000 annually per patient), with strong early-market uptake predicated on regulatory approval and reimbursement pathways.
- Long-term price projections suggest a gradual decline (20-40%) post-biosimilar entry, with total revenue potential in the multi-billion dollar range over a decade.
- Market success hinges on market access strategies, clinical differentiation, and adaptability to evolving policy and biosimilar landscapes.
- Continuous innovation, indications expansion, and strategic lifecycle management can sustain or grow profitability despite inherent competitive pressures.
FAQs
1. What factors influence the pricing of biologics like NDC 72733-5901?
Pricing is driven by manufacturing costs, clinical value, exclusivity rights, competitive landscape, payer negotiations, and regulatory considerations.
2. How do biosimilars impact the pricing and market share of biologics?
Biosimilars increase competition, typically reducing biologic prices by 20-40%, and can erode market share unless the innovator maintains differentiation or exclusivity.
3. What is the typical timeline for a biologic like NDC 72733-5901 from approval to market saturation?
FDA approval often occurs 8-12 years after initial patent filing; market saturation generally takes 5–10 years post-launch, influenced by clinical adoption and competition.
4. How do regulatory policies affect pricing strategies for new biologics?
Regulatory pathways can accelerate market entry, but reimbursement policies—especially value-based arrangements—significantly influence achievable pricing levels.
5. How can companies maximize revenue potential for biologics facing biosimilar competition?
Innovative formulations, expanded indications, lifecycle management, patient support programs, and contractual agreements with payers help sustain profitability.
Sources
- IQVIA Institute for Human Data Science, The Global Use of Medicine in 2022, 2022.
- Centers for Medicare & Medicaid Services, National Health Expenditure Data, 2022.
- GoodRx, Average Prices for Biologic Drugs, 2022.
- FDA, Biologics License Application (BLA) Process Overview, 2022.
- MarketWatch, Biologic Drugs Market Size and Forecast, 2022.
Note: Portions of this analysis are provisional, based on publicly available industry trends and typical biologic product characteristics. Specific product details for NDC 72733-5901 should be validated with proprietary sources for comprehensive financial modeling and strategic planning.
More… ↓
